Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

44 results about "Ophthalmia" patented technology

Ophthalmia (also called ophthalmitis) is inflammation of the eye. It is a medical sign which may be indicative of various conditions, including sympathetic ophthalmia (inflammation of both eyes following trauma to one eye), gonococcal ophthalmia, trachoma or "Egyptian" ophthalmia, ophthalmia neonatorum (a conjunctivitis of the newborn due to either of the two previous pathogens), photophthalmia and actinic conjunctivitis (inflammation resulting from prolonged exposure to ultraviolet rays), and others.

Chinese medicinal composition for treatment of edema and ophthalmia and preparation method thereof

InactiveCN104435457ASenses disorderBlood disorderSide effectStephania longa
The invention relates to a Chinese medicinal composition for treatment of edema and ophthalmia and a preparation method thereof. The Chinese medicinal composition is characterized by having the efficacy of clearing away heat and toxic materials, resisting inflammation, inducing diuresis and reducing edema, dispelling wind and removing obstruction in meridians, stopping bleeding, invigorating blood circulation and alleviating pain, etc., and can eliminate edema symptom proteinuria, hematuria, erythrocyte cylindruria, dropsy, high blood pressure, inflammation and the like. The matrix is prepared from the following Chinese medicinal composition and pharmaceutical excipients by weight: 1-50 parts of Scutellaria baicalensis, 1-100 parts of Stephania longa, 1-50 parts of acorus gramineus, and 1-50 parts of Pseudo-ginseng. The composition of the invention cares the whole of human body, prevents complications, treats both symptoms and root causes, has no toxic or side effect, and also has significant curative effect on some symptoms on which western medicines are non-effective. The composition provided by the invention is applied to clinical treatment of 12 edema cases, wherein the minimum age is 6 years old, the maximum age is 48 years old, the shortest disease course is 5 days, the longest disease course is 3 months, and all the cases are cured. The composition is applied to treatment of 26 ophthalmia cases, wherein the minimum age is 4 years old, the maximum age is 56 years old, the shortest disease course is 1 day, the longest disease course is 15 days, and all the cases are cured.
Owner:雷华亮
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products